Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, June 2006, p. 2255-2257, Vol. 50, No. 6
0066-4804/06/$08.00+0 doi:10.1128/AAC.00011-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Creighton University School of Medicine, Department of Medical Microbiology and Immunology, Center for Research in Anti-Infectives and Biotechnology, Omaha, Nebraska
Received 4 January 2006/ Accepted 19 March 2006
The in vitro activity of the novel quinolone DX-619 was compared to those of currently available quinolones against U.S. clinical isolates of Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus spp., Streptococcus pyogenes, and Streptococcus pneumoniae. DX-619 was the most potent quinolone overall, indicating possible utility as an anti-gram-positive quinolone.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |